Search Results
Apr 30, 2026, 04:21 ET Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160
novel trispecific antibody developed by Huahui Health using its proprietary PolyBoost™ multispecific antibody platform. HH160 simultaneously targets PD-1, CTLA-4, and VEGF-A, three clinically validated targets in cancer immunotherapy and anti-angiogenesis. Through its "three-in-one" synergistic mechanism
More news about: Huahui Health
Apr 29, 2026, 10:46 ET Thousands of attendees raise nearly $2 million for The Michael J. Fox Foundation at the 2026 Parkinson's Unity Walk
learn and connect while raising critical fund for a cure. The interactive day included thousands of people and families impacted by Parkinson's disease (PD) from all corners of the country and beyond for a 1.2-mile route around New York City's Central Park. The day also included educational programming and
More news about: The Michael J. Fox Foundation for Parkinson's Research
Apr 29, 2026, 10:00 ET European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
Europe), is the world's first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope
More news about: Henlius
Apr 29, 2026, 05:22 ET Energenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026
epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation (Phase II ready)ENERGI-F705PD – Tablet for Parkinson's disease (preparing for Phase II)Conference ContactContact at EWMA 2026: Mr. Winters FuEnergenesis
More news about: Energenesis Biomedical Co., Ltd.
Apr 29, 2026, 03:00 ET Coreline Soft Unveils 'G-BA Compliance-Optimized AI Infrastructure' in Step with Germany's Reimbursed Lung Cancer Screening Rollout
involved in Germany's lung cancer screening implementation:PD. Dr. Jens Vogel-Claussen (Charité Berlin): "LCS @ Charité Berlin" — Exploring the clinical implementation of screening.PD. Dr. med. Kaid Darwiche (Lungenklinik Hemer - University Medicine Bochum): "Modern
More news about: Coreline Soft
Apr 29, 2026, 03:00 ET Coreline Soft präsentiert „G-BA-konforme KI-Infrastruktur" zum Start der Kostenerstattung für das Lungenkrebs-Screening in Deutschland
deutschen Lungenkrebs-Screeningprogramms beteiligt sind:PD. Dr. Jens Vogel-Claussen (Charité Berlin): „LCS @ Charité Berlin" — Einblick in die klinische Umsetzung des Screenings.PD. Dr. med. Kaid Darwiche (Lungenklinik Hemer / University Medicine Bochum): „Moderne
More news about: Coreline Soft
Apr 28, 2026, 10:54 ET Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
the U.S., marking a new milestone in the Company's international registration capabilities for biosimilars. HLX43, an antibody-drug conjugate targeting PD-L1, is expected to create synergy with HLX07 or serplulimab injection for the treatment of advanced colorectal cancer and other solid tumors. HLX3901,
More news about: Fosun Pharma
Apr 28, 2026, 10:36 ET Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report
and pipeline innovative drugs have delivered several "world's first" breakthroughs. HANSIZHUANG became the world's first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), and has been approved for marketing in over 40 countries and
More news about: Fosun
Apr 28, 2026, 08:30 ET Bucking the Trend: HKEYBIO Slashes NHP Autoimmune Model Prices Amidst Global Monkey Shortage
QualityHKEYBIO's "Contrarian Promotion" is designed to help innovative drug developers generate the critical efficacy and pharmacokinetic (PK/PD) data, as well as clinical predictive biomarker analysis, needed for clinical transitions without exceeding their budgets. Key features of
More news about: HKeyBio
Apr 28, 2026, 08:00 ET Aligning Science Across Parkinson's and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments
research and drug development, while ensuring that researchers everywhere are working from a common, high-quality baseline.A full list of all PD Heterogeneity and Tool Generation teams and their work is available on the
More news about: Aligning Science Across Parkinson's
Apr 28, 2026, 07:00 ET BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.The Phase 2a expansion part of the trial is planned
More news about: BioLineRx Ltd.; Hemispherian AS
Apr 28, 2026, 04:07 ET Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
progression-free survival compared with pembrolizumab in first-line PD-L1-positive (TPS ≥1%) NSCLC. Based on these results, ivonescimab has been upgraded to a Class I recommendation for first-line treatment of both squamous and non-squamous NSCLC with PD-L1 TPS ≥1%. This indication was previously approved in China
More news about: Akeso, Inc.
Apr 27, 2026, 18:47 ET CANNON RESOURCES ANNOUNCES ROBUST PRELIMINARY ECONOMIC ASSESSMENT FOR THE FISHER EAST NICKEL PROJECT
recovery of approximately 84.4% into an approximately 11% Ni concentrate with an average of 0.24% Co and of 1.6 ppm Pd in concentratePayability assumptions of 80% Ni, 45% Co, and 50% PdClean concentrate with MgO below 4%, with no expected penalties and low deleterious elementsPERMITTING
More news about: Kinterra Capital Corp
Apr 27, 2026, 18:47 ET CANNON RESOURCES ANNOUNCES ROBUST PRELIMINARY ECONOMIC ASSESSMENT FOR THE FISHER EAST NICKEL PROJECT
recovery of approximately 84.4% into an approximately 11% Ni concentrate with an average of 0.24% Co and of 1.6 ppm Pd in concentratePayability assumptions of 80% Ni, 45% Co, and 50% PdClean concentrate with MgO below 4%, with no expected penalties and low deleterious elementsPERMITTING
More news about: Kinterra Capital Corp
Apr 27, 2026, 07:45 ET Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
zanidatamab plus chemotherapy further enhanced clinical benefit and marked the first immuno-oncology combination to show efficacy across both PD-L1–positive and PD-L1–negative tumors in this clinical setting," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of R&D, and chief
More news about: Jazz Pharmaceuticals plc
Apr 24, 2026, 07:30 ET HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a
More news about: HanchorBio Inc.
Apr 23, 2026, 09:30 ET AULUMU Wins Red Dot Design Award 2026 with M10 Power Bank and G05 Air 5-in-1 MagSafe Stand
usability, allowing seamless integration with MagSafe accessories even during charging. With support for multiple fast-charging protocols including PD, QC, and Qi2, the M10 reflects a thoughtful approach to universal compatibility and everyday convenience.More Than a Stand: G05 Air 5-in-1 MagSafe
More news about: AULUMU
Apr 23, 2026, 08:00 ET Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors
tolerability and antitumor activity of Repertoire's novel off-the-shelf T cell receptor (TCR) bispecific therapy as monotherapy and in combination with an anti-PD-1 therapyFirst asset derived from Repertoire's DECODETM platform to enter human trialsCAMBRIDGE,
More news about: Repertoire Immune Medicines
Apr 23, 2026, 07:00 ET Skymizer Taiwan Inc. 發表突破性架構 單卡實現超大型 LLM 推論
decode。每一塊矽晶片皆對應其最適合的階段。軟體堆疊——統一的 P/D 調度。Skymizer 的統一軟體堆疊——涵蓋 KV-cache 管理員、具階段感知能力的排程器，以及動態配置引擎——可協同調度 prefill 與 decode 資源池，於節點之間傳遞 KV-cache 狀態，並隨工作負載變動即時重新平衡 P:D 比例。「專為 decode 打造的硬體，搭配能協調每一份推論工作負載的智慧軟體堆疊——這才是在規模化場景下分離 P/D 的真正做法。」—— Luba Tang, Skymizer 技術長定義 AI
More news about: Skymizer Taiwan Inc.
Apr 23, 2026, 07:00 ET Skymizer Taiwan Inc. Unveils Breakthrough Architecture Enabling Ultra-Large LLM Inference on a Single Card
manager, phase-aware scheduler, and dynamic placement engine — orchestrates prefill and decode pools, carrying KV-cache state across nodes and rebalancing P:D ratios in real time as workloads shift."Purpose-built decode hardware paired with an intelligent software stack that orchestrates every inference
More news about: Skymizer Taiwan Inc.
Apr 22, 2026, 07:00 ET Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
approved the PD-L1 IHC 22C3 pharmDx test from Agilent Technologies as a companion diagnostic that detects PD-L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), and is indicated as an aid in identifying patients for treatment with KEYTRUDA, Merck's anti-PD-1 therapy.iiThe
More news about: Labcorp
Apr 22, 2026, 07:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
immune responses against cancer. It re-expresses TUSC2 protein in the cell and also increases the anti-tumor immune cell population and down-regulates PD-L1, thereby potentially boosting the immune response to cancer.REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based
More news about: Genprex, Inc.
Apr 22, 2026, 05:40 ET Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
approximately 27.32% of revenue.During the period, three innovative products and new indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.In terms of pipeline advancement, the Company obtained
More news about: Hengrui Pharma
Apr 22, 2026, 05:27 ET American Parkinson Disease Association Welcomes Three Distinguished Leaders to National Board of Directors
change."Sara Whittingham, MD, is an inspirational PD advocate, retired anesthesiologist, U.S. Air Force veteran, and accomplished IRONMAN competitor who brings both clinical expertise and lived experience to APDA. As a person living with PD, she has been a powerful voice for the community, submitting
More news about: American Parkinson Disease Association, Inc.
Apr 21, 2026, 22:10 ET Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
double-blind, placebo-controlled, multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of repeated intrathecal injections of RAG-17 in patients with SOD1 mutations. Since the first participant was successfully
More news about: Ractigen Therapeutics